What are ADC's

Our services

ADC Review
is made possible by:

NCT02363283 (Clinical Trial / Glembatumumab vedotin / CDX-011 / CR011-vcMMAE)

Study Title

Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma (NCT02363283)

Trial Description 

This phase II trial studies how well glembatumumab vedotin (also known as CDX-011 or CR011-vcMMAE) works in treating patients with middle layer of the wall of the eye (uveal) melanoma that has spread to other parts of the body (metastatic) or has returned at or near the same place after a period of time during which the cancer could not be detected (locally recurrent). Glembatumumab vedotin may shrink the tumor by binding to tumor cells and delivering tumor-killing substances to them.

This trial is sponsored by National Cancer Institute (NCI). [1]

Study Data

  • Condition: Uveal Melanoma
  • Interventions:
    • Drugs used in this trial
    • Other: Laboratory Biomarker Analysis
  • Phase: II
  • Estimated Enrollment: 32
  • Start: July 2015
  • Estimated Primary Completion: January 2017
  • Last verified: February 2015

Study Schematic 

(Coming soon)

Last Editorial review: July 8, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.



Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar